-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Clinical Lung Cancer published a retrospective study to evaluate the safety and efficacy of delayed administration (EI) of immune checkpoint inhibitor (ICI) in patients with non-small cell lung cancer under the influence of the new coronary pneumonia epidemic.
Recently, Clinical Lung Cancer published a retrospective study to evaluate the safety and efficacy of delayed administration (EI) of immune checkpoint inhibitor (ICI) in patients with non-small cell lung cancer under the influence of the new coronary pneumonia epidemic.
In this retrospective analysis, patients receiving ICI monotherapy or consolidation therapy or adjuvant ICI therapy were evaluated
In this retrospective analysis, patients receiving ICI monotherapy or consolidation therapy or adjuvant ICI therapy were evaluated
The study included 205 patients, of whom 117 received the EI dose and 88 received the SD dose
Among patients receiving pembrolizumab monotherapy, with a median follow-up of 93.
Among patients receiving durvalumab, with a median follow-up of 54.
Among patients receiving durvalumab, with a median follow-up of 54.
Among patients receiving nivolumab, with a median follow-up of 98.
Among patients receiving nivolumab, with a median follow-up of 98.
In conclusion, delayed administration (EI) of ICIs did not result in an increase in clinically relevant toxicity, leading to dose reduction and/or treatment discontinuation
In conclusion, delayed administration (EI) of ICIs did not result in an increase in clinically relevant toxicity, leading to dose reduction and/or treatment discontinuation
Original source:
Please cite this article as: LBM Hijmering-Kappelle et al, Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 PandemicAU: Please provide the academic degrees of corresponding author.
Please cite this article as: LBM Hijmering-Kappelle et al, Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 PandemicAU: Please provide the academic degrees of corresponding author.
, Clinical Lung Cancer, https://doi org/10 1016/j cllc 2021 12 005 COVID-19
Comment here
